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Clinical Infectious Diseases
MAJOR ARTICLE

Early Short-Course Corticosteroids in Hospitalized
Patients With COVID-19
1

Internal Medicine, Henry Ford Hospital, Detroit, Michigan, USA, 2Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA, 3Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA, and
Emergency Medicine, Henry Ford Hospital, Detroit, Michigan, USA

4

Background. There is no proven antiviral or immunomodulatory therapy for coronavirus disease 2019 (COVID-19). The disease progression associated with the proinflammatory host response prompted us to examine the role of early corticosteroid therapy
in patients with moderate to severe COVID-19.
Methods. We conducted a single pretest, single posttest quasi-experiment in a multicenter health system in Michigan from 12
March to 27 March 2020. Adult patients with confirmed moderate to severe COVID were included. A protocol was implemented
on 20 March 2020 using early, short-course, methylprednisolone 0.5 to 1 mg/kg/day divided in 2 intravenous doses for 3 days.
Outcomes of standard of care (SOC) and early corticosteroid groups were evaluated, with a primary composite endpoint of escalation of care from ward to intensive care unit (ICU), new requirement for mechanical ventilation, and mortality. All patients had at
least 14 days of follow-up.
Results. We analyzed 213 eligible subjects, 81 (38%) and 132 (62%) in SOC and early corticosteroid groups, respectively. The
composite endpoint occurred at a significantly lower rate in the early corticosteroid group (34.9% vs 54.3%, P = .005). This treatment
effect was observed within each individual component of the composite endpoint. Significant reduction in median hospital length
of stay was also observed in the early corticosteroid group (5 vs 8 days, P < .001). Multivariate regression analysis demonstrated an
independent reduction in the composite endpoint at 14-days controlling for other factors (adjusted odds ratio: 0.41; 95% confidence
interval, .22 – .77).
Conclusions. An early short course of methylprednisolone in patients with moderate to severe COVID-19 reduced escalation
of care and improved clinical outcomes.
Clinical Trials Registration. NCT04374071.
Keywords. Corticosteroids; outcomes; COVID-19; SARS-COV-2; coronavirus.

BACKGROUND

As of 9 April 2020, the United States has over 400 000 cases
of confirmed coronavirus disease 2019 (COVID-19) caused by
the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) [1]. Most patients will have mild illness, but older persons and those with comorbidities may develop severe disease
necessitating hospitalization and time in the intensive care unit
(ICU) [2, 3]. The disease pathophysiology presents in 2 distinct overlapping phases, the initial pathogenic viral response
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followed by host inflammatory response with grades of severity
associated with distinct clinical findings [4, 5]. The pathological progression in severe COVID-19 includes an excessive
and unregulated proinflammatory cytokine storm resulting
in immunopathological lung injury, diffuse alveolar damage
with the development of acute respiratory distress syndrome
(ARDS), and death [6–9].
In the absence of any proven antiviral therapy, the current
clinical management is primarily supportive care, supplemental oxygen, and mechanical ventilatory support [1, 10].
Adjunctive therapy with immunomodulatory agents targeting
the inflammatory cytokine storm are being evaluated [5, 10].
Studies of corticosteroid therapy for phylogenetically similar coronavirus infections showed no benefit and potential
harm [11]. Despite the frequent use in treating patients with
COVID-19 in China, the role of corticosteroids is undefined
[3, 5, 10–13]. A more recent observational study reported improved outcomes in patients with COVID-associated ARDS
that received corticosteroids [14].
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We postulated that early treatment with a short course of corticosteroids in patients with COVID-19 may attenuate the excessive host respiratory and systemic inflammatory responses. We
report the clinical characteristics and early outcomes of patients
with COVID-19 receiving short courses of methylprednisolone.
METHODS

Consecutive patients hospitalized from 12 March 2020 through
27 March 2020 were eligible for inclusion if they were ≥18 years,
had confirmed COVID-19 infection, with radiographic evidence of bilateral pulmonary infiltrates, and required oxygen
by nasal cannula, high-flow nasal cannula (HFNC), or mechanical ventilation. Patients were excluded if they were transferred
from an out-of-system hospital, died within 24 hours of presentation to the emergency department (ED), or were admitted
for <24 hours. A confirmed case of COVID-19 was defined as
a patient that had a positive reverse-transcription polymerase
chain reaction (RT-PCR) assay for SARS-CoV-2 in a nasopharyngeal sample tested by the Michigan Department of Health
and Human Services (MDHHS) or the Henry Ford Health
System (HFHS) centralized clinical microbiology laboratory.
Beginning 16 March 2020, testing for hospitalized patients was
performed by the centralized clinical microbiology laboratory.
Patients were risk stratified by severity of symptoms on
presentation to the hospital as mild, moderate, or severe
COVID-19. Patients without hypoxia or exertional dyspnea
were considered to have mild COVID-19. Patients with mild
COVID-19 were treated with symptom relief only and not admitted to the hospital. Patients who presented with infiltrates on
chest radiography and required supplemental oxygen by nasal
cannula or HFNC were classified as having moderate COVID19. Patients who had respiratory failure requiring mechanical
ventilation were classified as having severe COVID-19.
Study Design

This was a multicenter quasi-experimental study at HFHS, composed of 5 hospitals in southeast and south-central Michigan.
The study was approved by the institution’s Investigational
Review Board (13739) with waiver of consent. Patients in the
standard of care (SOC) group from 12 March 2020 through 19
March 2020 were compared to an early corticosteroid group that
included patients from 20 March 2020 through 27 March 2020.
Patients in both study groups received standard care, composed of supplemental oxygen, HFNC, invasive ventilation,
antibiotic agents, antiviral agents, vasopressor support, and renalreplacement therapy, as determined by the primary team. Patients
who progressed to ARDS were managed with SOC [15].

Early Corticosteroid Group

As a result of observed poor outcomes, clinical rationale based
on immunology, clinical course of COVID-19, and more recently
best available evidence, the HFHS early corticosteroid protocol
was developed (Supplementary Materials) [14, 15, 17]. We hypothesized that early corticosteroids would combat the inflammatory cascade leading to respiratory failure, ICU escalation of care,
and mechanical ventilation. The early corticosteroid protocol
was incorporated in the institutional COVID-19 guidelines on
20 March 2020. Patients with confirmed influenza infection were
not recommended to receive early corticosteroids. The decision to
prescribe hydroxychloroquine and early corticosteroids was at the
discretion of the primary medical team.
Moderate COVID-19 was treated with hydroxychloroquine
400 mg twice daily for 2 doses on day 1, followed by 200 mg
twice daily on days 2–5. Patients with moderate COVID-19 who
required 4 liters or more of oxygen per minute on admission, or
who had escalating oxygen requirements from baseline, were
recommended to receive IV methylprednisolone 0.5 to 1 mg/
kg/day in 2 divided doses for 3 days. Patients who required ICU
admission were recommended to receive the above regimen of
hydroxychloroquine and IV methylprednisolone 0.5 to 1 mg/
kg/day in 2 divided doses for 3–7 days. ICU patients were also
evaluated for tocilizumab on a case-by-case basis. Oral switch
was performed to prednisone at a ratio of 1 to 1 when determined clinically appropriate by the primary medical team.
Data Collection

Data were ascertained from each institution’s electronic medical
record and recorded in a standardized electronic case report
form. Demographic data, information on clinical symptoms
or signs at presentation, and laboratory and radiologic results
during admission were collected. All laboratory tests and radiologic assessments, including plain chest radiography and
computed tomography of the chest, were performed at the discretion of the treating physician.

Intervention Standard of Care

Study Definitions

Patients with moderate or severe disease who presented to HFHS
within the first week of the COVID epidemic in Detroit were

We ascertained coexisting conditions from electronic medical record and physician documentation. The National Early
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Study Population

initially treated with supportive care with or without a combination of lopinavir-ritonavir and ribavirin or hydroxychloroquine according an institutional guideline developed by Infectious Diseases
Physicians and Pharmacists. The institutional guidelines were developed by consensus, and based on the available literature, experience
from Wuhan, China, and other centers around the world affected
by COVID-19 before Michigan. Intravenous (IV) remdesivir compassionate use was requested for eligible mechanically ventilated
patients. On 17 March 2020 lopinavir-ritonavir with ribavirin was
removed from the COVID-19 institutional protocol [16]. Steroids
were considered on a case-by-case basis.

Warning Score (NEWS) was collected to evaluate baseline illness severity based on vital signs obtained in the ED [18].
Additionally, the quick Sequential Organ Failure Assessment
was used to evaluate severity of illness of included patients
based on ED vitals and examination [19]. All patients were followed for at least 14 days after initial presentation. Patient data
were censored on 9 April 2020.

Primary Endpoint

The primary composite endpoint was escalation to an ICU
from a general medical unit, progression to respiratory failure
requiring mechanical ventilation after hospital admission, or
in-hospital all-cause mortality. Patients directly admitted to the
ICU from the emergency room were evaluated for the latter 2
outcomes, and those requiring mechanical ventilation in the
emergency room were evaluated for mortality.
Secondary Endpoints

Secondary endpoints included development and severity of
ARDS, days to ventilator liberation, shock, acute kidney injury
(AKI), and length of hospital stay (LOS). LOS was reported
only for patients who were discharged alive within the 14-day
minimum follow-up period. ARDS was diagnosed and classified according to the Berlin definition [20]. AKI was diagnosed
according to the Kidney Disease: Improving Global Outcomes
definition [21].
Statistical Analysis

Continuous variables were reported as median and interquartile range (IQR) and compared using the Mann-Whitney test or
t-test, as appropriate. Categorical data were reported as number
and percentage (no., %) and compared using the χ 2 test or Fisher
exact test, as appropriate. No imputation was made for missing
data points. The sample size was derived from all eligible consecutive hospitalized patients during the study period. A 2-sided
α < 0.05 was considered statistically significant. Bivariate and
multivariable logistic regression analysis was planned a priori
to test the association between the composite endpoint and exposure to the corticosteroid protocol. Covariates in the bivariate
analysis with a P-value <.2 and clinical rationale were included
in a multivariable regression model that was restricted to a
subject-to-variable ratio of 10:1. To evaluate the implementation timing of the in-house RT-PCR SARS-CoV-2 testing a post
hoc sensitivity analysis were conducted on the composite outcome. A nonequivalent dependent variable, receipt of, and time
to empiric antibiotic therapy for pneumonia, was utilized to account for potential maturation in the management of COVID19. Statistical analysis was performed using IBM SPSS version
25 (Chicago, IL) and SAS 9.4 (Cary, NC).

Two-hundred and fifty consecutive patients were evaluated for
inclusion. Ten were hospitalized for ≤24 hours, 23 did not require oxygen by nasal cannula, HFNC, or mechanical ventilation, and 4 expired within 24 hours of admission (Figure 1).
Two-hundred and thirteen patients were included, 81 (38%) in
the SOC group and 132 (62%) in the early corticosteroid group.
The median age of the SOC group and early corticosteroid group
was 64 (IQR: 51.5, 73.5) and 61 (IQR: 51, 72) years, respectively.
Black patients comprised 61.7% of the SOC group and 79.5%
of the early corticosteroid group (P = .005). Of the comorbid
conditions evaluated, chronic obstructive pulmonary disease
was more frequent in the SOC group compared to the early
corticosteroid group (18.5% vs 9.1%; P = .045). The presenting
COVID-19 symptoms, baseline severity of illness, and other
demographics are presented in Table 1. One patient had a concomitant influenza infection in the early corticosteroid group.
Overall, corticosteroids use was 56.8% and 68.2% in the SOC
group and early corticosteroid group, respectively (P = .094).
The early corticosteroid group had a greater proportion of corticosteroids initiated within 48 hours of presentation (12.4%
vs 41.7%, P < .001), with a median time to initiation of 2 days
(IQR: 1–3, range 0–8) as compared to 5 days (IQR: 3–7, range
1–9) in the SOC. The median time to hydroxychloroquine initiation was greater in the SOC group compared to the early corticosteroid group (3 [IQR: 1, 4] vs 1 [IQR: 0, 2] days, P < .126).
Additional treatment characteristics are described in Table 2.
The primary composite endpoint occurred at a significantly
lower rate in the early corticosteroid group compared to the
SOC group (34.9% vs 54.3%, P = .005). A significant reduction in each of primary composite endpoints was also noted
(Table 3). In the sensitivity analysis subgroup, after the implementation of the in-house RT-PCR SARS-CoV-2 testing, 34.9%
(46 of 132 patients) and 55% (33 of 60 patients) experienced the
primary composite endpoint in the early corticosteroid group
and SOC group, respectively (P = .009). After adjustment for
male sex, NEWS of ≥7, and age ≥60, early corticosteroid initiation was independently associated with a reduction in the
composite endpoint at 14 days (adjusted odds ratio: 0.41; 95%
confidence interval [CI], (.22 – .77) (Table S2, Supplemental
Materials).
The median LOS was significantly reduced from 8 days in
the SOC group, to 5 days in the early corticosteroid group
(P < .001). ARDS occurred in 38.3% and 26.6% in the SOC
group and early corticosteroid group, respectively (P = .04).
Outcomes at 14 days also included 9 (11.1%) of SOC patients
remaining admitted as compared to 26 (19.7%) of early corticosteroid patients. Table 3 describes additional outcomes
before and after implementation of the early corticosteroid
protocol.
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OUTCOME MEASURES

RESULTS

Table 1.

Baseline Demographics and Clinical Characteristics of Study Patients

Characteristics

Total
(n = 213)

SOC (n = 81)

62 (51–62)

64 (51.5–3.5)

Early CG (n = 132)

P value

Demographics
Median age (IQR), y

61 (51–72)

.400

Male sex, no. (%)

109 (51.2)

41 (50.6)

68 (51.5)

.899

Black race, no. (%)

155 (72.8)

50 (61.7)

105 (79.5)

32 (27.3–38.7)

30 (25–39)

33.2 (28.9–38.5)

.004
.007

Coexisting conditions, no. (%)
Asthma

33 (15.5)

16 (19.8)

17 (12.9)

.180

Chronic kidney disease

98 (46)

41 (51.9)

57 (43.5)

.240

Chronic obstructive pulmonary disease

27 (12.7)

15 (18.5)

12 (9.1)

.045

Congestive heart failure

26 (12.2)

10 (12.5)

16 (12.2)

.951

Coronary artery disease

38 (17.8)

18 (22.2)

20 (15.2)

.192

Diabetes

105 (49.3)

37 (45.7)

68 (51.5)

.411

Hypertension

158 (74.2)

62 (76.5)

96 (72.7)

.925

Malignancy

24 (11.3)

11 (13.6)

13 (9.9)

.405

Smoking history

88 (41.3)

40 (49.4)

48 (36.4)

.062

Cough, no. (%)

158 (74.2)

62 (76.5)

96 (72.7)

.536

Fever, no. (%)

150 (70.4)

57 (70.4)

93 (70.5)

.989

85 (39.9)

32 (39.5)

53 (40.2)

.926

148 (69.5)

50 (61.7)

98 (74.2)

.054

5 (3–7)

5 (2–7)

6 (3–7)

.107

Median qSOFA (IQR)

1 (0–1)

1 (0–1)

1 (0–1)

.850

Median NEWS (IQR)

7 (4–10)

7 (4–10)

7 (4–9)

.668

Requiring mechanical ventilation in ED, no. (%)

22 (10.3)

10 (12.3)

12 (9.1)

.448

Direct admission to ICU, no. (%)

26 (12.2)

11 (13.6)

15 (11.4)

.631

Symptoms

Myalgia, no. (%)
Shortness of breath, no. (%)
Median duration of symptoms (IQR), d
Severity of illness in ED

Abbreviations: CG, corticosteroid group; ED, emergency department; ICU, intensive care unit; IQR, interquartile range; NEWS, National Early Warning Score; qSOFA, quick Sequential Organ
Failure Assessment; SOC, standard of care.

Table 2.

Treatments Received by Groups
Total
(n = 213)

Treatment

SOC (n = 81)

Early CG (n = 132)

P value

Antimicrobials
Empiric antibiotic prescribed for pneumonia, no. (%)

163 (76.5)

65 (80.2)

98 (74)

.316

Median time to empiric antibiotics (IQR), d

1 (0–1)

1 (0–1)

0 (0–1)

.631

Median duration of antimicrobials (IQR), d

4 (2–5)

5 (3–5)

3 (2–5)

.009

Hydroxychloroquine use, no. (%)

161 (75.6)

Median time to hydroxychloroquine initiation (IQR), d
Lopinavir/ritonavir and ribavirin use, no. (%)

57 (70.4)

104 (78.8)

.167

2 (1–3)

3 (1–4)

1 (0–2)

.126

10 (4.7)

9 (11.1)

1 (0.76)

.001

Remdesivir use, no. (%)

5 (2.3)

5 (6.2)

0 (0)

.004

Tocilizumab use, no. (%)

14 (6.6)

8 (10.1)

6 (4.5)

.126

Corticosteroid treatment
Median time to steroid initiation from admission (IQR), d

2 (1–4)

5 (3–7)

2 (1–3)

<.001

Corticosteroids received in first 48 h, no. (%)

65 (30.5)

10 (12.4)

55 (41.7)

<.001

Corticosteroids received at any time, no. (%)a

136 (63.8)

46 (56.8)

90 (68.2)

.094

Methylprednisolone use, no. (%)

129 (94.9)

43 (93.5)

86 (95.5)

.688

Median methylprednisolone dose (IQR), mg

40 (35–50)

40 (40–50)

40 (40–50)

Oral prednisone switch, no. (%)

7 (5.4)

5 (11.6)

2 (2.3)

.041

Median duration of corticosteroids (IQR), db

3 (3-3)

3 (3-3)

3 (3-3)

.812

Abbreviations: CG, corticosteroid group; IQR, interquartile range; SOC, standard of care.
a

Refer to Figure S1, supplemental materials for description of timing.

b

29 patients received greater than 3 days; Early corticosteroid group 20 (22.2), 9 SOC (19.5).
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Median body mass index (IQR) - kg/m2

Table 3.

Outcomes in Standard of Care and Early Corticosteroid Group

Outcomes

SOC (n = 81)

Early CG (n = 132)

Odds Ratio (CI)

P value

Primary outcome
Primary composite outcome, no. (%)

46 (34.9)

.45 (.26–.79)

.005

21 (26.3)

18 (13.6)

.45 (.22–.91)

.024

Respiratory failure requiring mechanical ventilation, no. (%)a

26 (36.6)

26 (21.7)

.47 (.25–.92)

.025

Escalation from GMU to ICU, no. (%)b

31 (44.3)

32 (27.3)

.47 (.25–.88)

.017

.51 (.28–.90)

Secondary outcomes
Overall mechanical ventilation, no. (%)

36 (44.4)

38 (28.8)

ARDS, no. (%)

31 (38.3)

33 (26.6)

.020
.040

Mild

3 (3.7)

1 (0.76)

.125

Moderate

8 (9.9)

9 (6.8)

.307

20 (24.7)

23 (17.4)

.201

8 (4–13)

7 (4–9)

.558

Severe
Median duration of mechanical ventilation (IQR), d

8 (4–13)

7 (4–9)

.558

Shock, no. (%)

Median time to extubation (IQR), d

19 (23.5)

17 (12.6)

.069

Acute kidney injury, no. (%)

42 (51.9)

59 (44.7)

Median hospital length of stay (IQR), d

8 (5–14)

Discharged from hospital, no. (%)

5 (3–7)

.310
<.001

51 (62.2)

88 (66.7)

.584

Remain hospitalized, no. (%)

9 (11.1)

26 (19.7)

.102

Remain intubated, no. (%)

7 (8.6)

13 (9.8)

.771

Abbreviations: ARDS, acute respiratory distress syndrome; CI, confidence interval; CG, corticosteroid group; GMU, general medical unit; ICU, intensive care unit; IQR, interquartile range;
SOC, standard of care.
a
A total of 10 and 12 patients were not included in this analysis because they required mechanical ventilation in the emergency department in the SOC and early corticosteroid groups,
respectively.
b
A total of 11 and 15 patients were not included in this analysis because they were directly admitted to the ICU in the SOC and early corticosteroid groups, respectively.

DISCUSSION

In this quasi-experimental study, hospitalized patients with
moderate to severe COVID-19 that received an early short
course of methylprednisolone had a reduced rate of the primary composite endpoint of death, ICU transfer, and mechanical ventilation, with a number needed to treat of 8 to prevent
1 patient transfer for mechanical ventilation. The reduction in
ICU transfer and requirement for mechanical ventilation represents a potential intervention to reduce critical care utilization

during the COVID-19 pandemic [22, 23]. The median reduction of hospital LOS by 3 days observed with the use of corticosteroids could positively impact hospital capacity during the
COVID-19 surge.
Corticosteroids are not routinely recommended in patients
with COVID-19 without an alternate indication or presence
of ARDS [11, 15, 24]. Data are conflicting; corticosteroid use
in previous viral respiratory illnesses has demonstrated delayed viral clearance and increased mortality [11, 25]. On the

250 paents underwent
screening
37 excluded
10 hospitalized < 24 hours
23 did not require supplemental oxygen
4 expired within 24 hours of presentaon
0 transfer from out-of-system hospital
213 included

81 admied to standard of
care group

Figure 1.

132 admied to early
corcosteroid group

Number of patients screened and included in the trial.
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44 (54.3)

Death, no. (%)
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may have been subject to channeling bias. Prone ventilation was
attempted in a single SOC group patient and then not utilized
again until late March. This may have impacted development of
the primary outcome in the subset patients who required mechanical ventilation. Finally, the study has a limited follow-up
period of 14 days and may be subject to lead-time bias, similar
to other recent reports. As of 9 April 2020, 51 (62.9%) of patients in the SOC cohort and 88 (66.7%) of patients in the early
corticosteroid cohort were discharged from the hospital. As a
result, outcomes for those patients are not known. Anecdotally,
we observed hyperglycemia but no severe corticosteroid related
adverse effects (ie, gastrointestinal hemorrhage), and data collection is ongoing.
In conclusion, early use of a short course of
methylprednisolone, an inexpensive and readily available agent,
in patients with moderate to severe COVID-19 may prevent
progression of disease and improve outcomes. These findings
are crucial given the ongoing COVID-19 pandemic and ICU
bed and mechanical ventilator shortages. Research is urgently
needed to further define the role of corticosteroids in patients
with COVID-19 at a high risk of clinical deterioration, identified early in the disease course using prognostic markers or
clinical prediction tools.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online.
Consisting of data provided by the authors to benefit the reader, the posted
materials are not copyedited and are the sole responsibility of the authors, so
questions or comments should be addressed to the corresponding author.
Notes
#

Henry Ford COVID-19 Management Task Force. Varidhi Nauriyal, MD,1,2
Jayanth Lakshmikanth, MD,2 Asif Abdul Hamed, MD,2 Owais Nadeem,
MD,2 Kristin Griebe, PharmD,3 Joseph M. Johnson, PharmD,3 Patrick
Bradley, MD,2 Junior Uduman, MD,2 Sara Hegab, MD,2 Jennifer Swiderek,
MD,2 Amanda Godfrey, MD,2 Jeffrey Jennings, MD,2 Jayna Gardner-Gray,
MD,5 Adam Ackerman, MD,6 Jonathan Lezotte, MD,6 Joseph Ruhala, MD,6
Linoj Samuel, PhD, D(ABMM),7 Robert J. Tibbetts, PhD, D(ABMM),
F(CCM),7 Indira Brar, MD,1 John McKinnon, MD,1 Geehan Suleyman,
MD,1 Nicholas Yared, MD,1 Erica Herc, MD,1 Jonathan Williams, MD,1
Odaliz Abreu Lanfranco, MD,1 Anne Chen, MD,1 Marcus Zervos, MD.1
Acknowledgments. Eric Scher, MD,4 for his leadership and commitment
to education in the field of Academic Internal Medicine. Krishna Modi, MD,4
Rebecca Bussa, Kelly Curran, MD,4 Abigail Entz, MD,4 Hafsa Abdulla, MD,4 and
Charles Hammond, MD,4 for data collection and review. The authors thank the
entire front-line staff members of the Henry Ford Health Systemfor dedicated
and compassionate patient care during the COVID-19 outbreak.
1
Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA,
2
Pulmonary Medicine, Henry Ford Hospital, Detroit, Michigan, USA,
3
Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA, 4Internal
Medicine, Henry Ford Hospital, Detroit, Michigan, USA, 5Emergency
Medicine, Henry Ford Hospital, Detroit, Michigan, USA, 6Surgical Critical
Care, Henry Ford Hospital, Detroit, Michigan, USA, 7Pathology and
Microbiology, Henry Ford Hospital, Detroit, Michigan, USA.
Potential conflicts of interest. S. H. received speakers’ bureau honoraria
from Bayer. I. B. received speakers’ bureau honoraria from Gilead, ViiV, and
Jansssen. All other authors report no potential conflicts. All authors have
submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Downloaded from https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa601/5840526 by Henry Ford Hospital user on 14 August 2020

contrary, short-course corticosteroids in some reports are beneficial and safe in critically ill patients with SARS-CoV-2 and
were not found to be an independent risk factor of prolonged
viral RNA shedding [17, 26, 27]. These discordant findings
may be explained by the observational nature of the studies,
heterogeneity in patient acuity, inconsistent dosing regimens
and duration, and timing of initiation of therapy [10, 17].
Corticosteroids were used in 11–35% of nonsevere and 45–72%
of severe COVID-19 cases in China; however, the benefits and
risks remain undefined [2, 6, 12–14]. A mortality benefit (hazard
ratio, 0.38; 95% CI, .20–.72) with the use of methylprednisolone
was reported in 1 retrospective cohort study of COVID-19 patients with ARDS [14].
COVID-19 can progress from mild to severe illness characterized by an initial viral infection phase followed by pulmonary inflammation, and then a hyper-inflammation phase [4, 6,
9]. The pulmonary phase is associated with progressive dyspnea
and radiographic findings of pneumonia [4]. Symptom onset
to dyspnea and ARDS development occurs between a median
of 5–7 days and 8–12 days, respectively [6, 12, 28]. The present
study findings support that timing is key. An early course of
corticosteroid, specifically methylprednisolone, at the onset of
dyspnea, may attenuate progression to the hyper-inflammation
phase that requires escalation of care in patients with COVID19. In this study, 3 days of early corticosteroids were administered at a median 2 days into hospitalization and 8 days from
symptom onset. However, the administration of a 3-day course
of corticosteroids later in the disease course (median 5 days after
hospitalization), as occurred in our SOC group, did not appear
to confer the same benefit. Hydroxychloroquine with or without
azithromycin, remdesivir, and lopinavir/ritonavir with ribavirin
were prescribed at similar frequency between groups. These
agents have demonstrated mixed efficacy results for COVID-19
in placebo controlled-trials, with hydroxychloroquine being the
most promising at this time [10]. Immunomodulatory agents,
such as tocilizumab, were infrequently used in this study.
This study has several limitations. Given the pandemic nature of the disease, a pragmatic quasi-experimental design was
used, and there are some differences in the baseline characteristics of the comparator groups. The potential for regression
to the mean and maturation is an inherent limitation to all
quasi-experiments. On 16 March 2020, rapid on-site RT-PCR
testing for SARS-CoV-2 testing was implemented, and some of
the SOC group experienced delayed diagnosis and treatment.
However, the observed association was unchanged in the sensitivity analysis. A nonequivalent dependent variable, empiric
antibiotic therapy for pneumonia, suggested no difference in
management of COVID-19. Some of the SOC group received
corticosteroids after initiation of the updated COVID-19 institutional treatment protocol. Steroids initiated in this group
were started significantly later. Additionally, guideline adherence in the early corticosteroid group was not universal, and
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